grant
Investigating mechanisms of bladder tumorigenesis and therapeutic resistance
Organization DIVISION OF BASIC SCIENCES - NCILocation UNITED STATES
NIHUS FederalResearch GrantFY2025AddressAmino AcidsAreaAutomobile DrivingBehaviorBiologicalBladderBladder CancerBladder NeoplasmBladder TumorsBladder Urinary SystemCRISPRCRISPR/Cas systemCancer BiologyCancer GenesCancer-Promoting GeneCancersCell SurvivalCell ViabilityCessation of lifeClustered Regularly Interspaced Short Palindromic RepeatsDNA AlterationDNA Sequence AlterationDNA mutationDataDeaminaseDeathDeath RateDevelopmentDiseaseDisorderDrug resistanceDrugsEnzyme GeneEnzymesEvaluationEvolutionFDA approvedFunctional RNAGene TranscriptionGenesGeneticGenetic AlterationGenetic ChangeGenetic TranscriptionGenetic defectGenetic mutationGenetics-MutagenesisGenomic approachGenomicsGoalsHeterogeneityImmuneImmune mediated therapyImmunesImmunologically Directed TherapyImmunotherapyIn VitroIntratumoral heterogeneityLaboratoriesMalignantMalignant - descriptorMalignant Bladder NeoplasmMalignant CellMalignant NeoplasmsMalignant TumorMalignant Tumor of the BladderMalignant neoplasm of urinary bladderMediatingMedicationMetastasisMetastasizeMetastatic LesionMetastatic MassMetastatic NeoplasmMetastatic TumorModelingMolecularMuscleMuscle TissueMutagenesisMutagenesis Molecular BiologyMutationNeoplasm MetastasisNon-Polyadenylated RNANoncoding RNANontranslated RNAOncogenesOncogenesisPathway interactionsPatient outcomePatient-Centered OutcomesPatient-Focused OutcomesPatientsPharmaceutical PreparationsPhenotypePredispositionProcessProteinsRNARNA ExpressionRNA Gene ProductsRNA SplicingRecurrenceRecurrentRegulationReportingResearchResistanceResistance developmentResistant developmentRibonucleic AcidRoleSecondary NeoplasmSecondary TumorSequence AlterationShapesSpecific qualifier valueSpecifiedSplicingSusceptibilityTherapeuticTranscriptionTranscription ProcessTransforming GenesTumor CellTumor SubtypeTumor Suppressor ProteinsUntranslated RNAUrinary Bladder CancerUrinary Bladder Malignant TumorUrinary Bladder NeoplasmUrinary Bladder Tumoraminoacidbiologiccancer cellcancer cell genomecancer genomecancer metastasiscancer progressiondeveloping resistancedevelopmentaldriver lesiondriver mutationdrivingdrug efficacydrug resistantdrug/agenteffective therapyeffective treatmentepithelial to mesenchymal transitionfunctional genomicsgenome mutationgenomic alterationgenomic effortgenomic strategyheterogeneity in tumorsimmune microenvironmentimmune therapeutic approachimmune therapeutic interventionsimmune therapeutic regimensimmune therapeutic strategyimmune therapyimmune-based therapiesimmune-based treatmentsimmuno therapyimmunosuppressive microenvironmentimmunosuppressive tumor microenvironmentimprovedin vivoinsightinterestintra-tumoral heterogeneityintratumor heterogeneitymalignancymortality ratemortality ratiomultiomicsmultiple omicsmuscularneoplasm progressionneoplasm/cancerneoplastic cellneoplastic progressionnoncodingnovelpanomicspathwaypatient oriented outcomespersonalization of treatmentpersonalized medicinepersonalized therapypersonalized treatmentposttranscriptionalpressureresistance to Drugresistance to therapyresistantresistant to Drugresistant to therapyresponse to therapyresponse to treatmentsocial roletherapeutic resistancetherapeutic responsetherapeutic targettherapy resistanttherapy responsetranscriptomicstreatment resistancetreatment responsetreatment responsivenesstreatment strategytumortumor cell metastasistumor genometumor heterogeneitytumor immune microenvironmenttumor progressiontumor suppressortumor-immune system interactionstumorigenesisurinary bladder
Description preview
Bladder cancer is the ninth most common malignancy globally, with over 600,000 new cases and 220,000 deaths reported in 2022. Despite recent therapeutic advances, treatment resistance remains a major challenge, contributing to persistently high mortality rates. The overarching goal of our laboratory is to elucidate the molecular mechanisms driving…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click